Clinica chimica acta; international journal of clinical chemistry · 2026
Serum IgG, definite anti-dsDNA positivity, and advanced HBV-related liver disease: a laboratory-based retrospective study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Hui, Han Xue, Qian Chen, Jiang Shuo, Zheng Guojun, Zhang Zhou
Аннотация
BACKGROUND: Immune-serological abnormalities may accompany chronic hepatitis B virus (HBV)-related disease progression, but the relevance of serum immunoglobulin G (IgG) and definite anti-double-stranded DNA (anti-dsDNA) positivity in this setting remains unclear. This study examined their associations with advanced HBV-related liver disease.
METHODS: This retrospective laboratory-based study included 150 patients with HBV-related liver disease, comprising 50 patients with chronic hepatitis B (CHB), 50 with liver cirrhosis (LC), and 50 with hepatocellular carcinoma (HCC). Advanced HBV-related liver disease was defined as LC or HCC. Multivariable logistic regression was used to evaluate the associations of serum IgG and definite anti-dsDNA positivity with advanced disease after adjustment for age, sex, and antiviral treatment history. Stage-specific analyses, exploratory joint stratification, restricted cubic spline analysis, and sensitivity analyses were also performed.
RESULTS: Serum IgG levels were higher and definite anti-dsDNA positivity was more frequent in patients with advanced HBV-related liver disease than in those with CHB. In the primary multivariable model, serum IgG was associated with advanced disease (OR 1.24 per 1 g/L increase, 95% CI 1.03-1.48, P = 0.021), whereas definite anti-dsDNA positivity showed a positive but statistically borderline association (OR 3.72, 95% CI 0.98-14.20, P = 0.054). Stage-specific analyses suggested that serum IgG was more evident in the CHB-to-LC comparison, whereas definite anti-dsDNA positivity was more evident in the CHB-to-HCC comparison, although estimates involving anti-dsDNA positivity were imprecise. Exploratory joint stratification showed the highest estimated odds of advanced disease among patients with both high serum IgG and definite anti-dsDNA positivity, but subgroup size was small.
CONCLUSIONS: Serum IgG showed the most consistent association with advanced HBV-related liver disease in this exploratory laboratory-based cohort. Definite anti-dsDNA positivity showed a weaker, less stable, and stage-dependent signal. These findings suggest that immune-serological markers may provide complementary laboratory information across the HBV-related disease spectrum, but they require validation in larger consecutive cohorts.
METHODS: This retrospective laboratory-based study included 150 patients with HBV-related liver disease, comprising 50 patients with chronic hepatitis B (CHB), 50 with liver cirrhosis (LC), and 50 with hepatocellular carcinoma (HCC). Advanced HBV-related liver disease was defined as LC or HCC. Multivariable logistic regression was used to evaluate the associations of serum IgG and definite anti-dsDNA positivity with advanced disease after adjustment for age, sex, and antiviral treatment history. Stage-specific analyses, exploratory joint stratification, restricted cubic spline analysis, and sensitivity analyses were also performed.
RESULTS: Serum IgG levels were higher and definite anti-dsDNA positivity was more frequent in patients with advanced HBV-related liver disease than in those with CHB. In the primary multivariable model, serum IgG was associated with advanced disease (OR 1.24 per 1 g/L increase, 95% CI 1.03-1.48, P = 0.021), whereas definite anti-dsDNA positivity showed a positive but statistically borderline association (OR 3.72, 95% CI 0.98-14.20, P = 0.054). Stage-specific analyses suggested that serum IgG was more evident in the CHB-to-LC comparison, whereas definite anti-dsDNA positivity was more evident in the CHB-to-HCC comparison, although estimates involving anti-dsDNA positivity were imprecise. Exploratory joint stratification showed the highest estimated odds of advanced disease among patients with both high serum IgG and definite anti-dsDNA positivity, but subgroup size was small.
CONCLUSIONS: Serum IgG showed the most consistent association with advanced HBV-related liver disease in this exploratory laboratory-based cohort. Definite anti-dsDNA positivity showed a weaker, less stable, and stage-dependent signal. These findings suggest that immune-serological markers may provide complementary laboratory information across the HBV-related disease spectrum, but they require validation in larger consecutive cohorts.